ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

CVKD Cadrenal Therapeutics Inc

0.4559
-0.0295 (-6.08%)
11 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Cadrenal Therapeutics Inc CVKD NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.0295 -6.08% 0.4559 09:01:17
Open Price Low Price High Price Close Price Previous Close
0.48 0.4591 0.504 0.46 0.4854
more quote information »

Recent News

Date Time Source Heading
09/5/202423:00PRNUSCadrenal Therapeutics Provides First Quarter 2024 Corporate..
09/5/202420:23EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/4/202406:30PRNUSCadrenal Therapeutics to Participate in Noble Capital..
09/4/202423:00PRNUSCadrenal Therapeutics Receives FDA Orphan Drug Designation..
12/3/202400:15EDGAR2Form 8-K - Current report
12/3/202400:00PRNUSCadrenal Therapeutics Provides Fourth Quarter 2023 Corporate..
06/3/202409:24EDGAR2Form 8-K - Current report
27/2/202401:00PRNUSCadrenal Therapeutics to Participate at Technology and Heart..
16/2/202400:00EDGAR2Form 8-K/A - Current report: [Amend]
13/2/202408:49EDGAR2Form 8-K - Current report
09/2/202401:00PRNUSCadrenal Therapeutics Appoints Jeff Cole as Chief Operating..
01/2/202401:00PRNUSCadrenal Therapeutics Highlights Publication of..
25/1/202401:00PRNUSCadrenal Therapeutics to Participate in a Fireside Chat at..
05/1/202401:00PRNUSCadrenal Therapeutics to Present at the Biotech Showcase on..
20/12/202301:00PRNUSNoble Capital Markets Initiates Coverage on Cadrenal..
13/12/202301:00PRNUSCadrenal Therapeutics Engages The Sage Group to Advance..
01/12/202308:15PRNUSCadrenal Therapeutics to Present at the NobleCon 19..
10/11/202301:15EDGAR2Form 8-K - Current report
10/11/202301:00PRNUSCadrenal Therapeutics Provides Third Quarter 2023 Corporate..
10/11/202300:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
24/10/202308:04EDGAR2Form 8-K - Current report
10/10/202307:15PRNUSCadrenal Therapeutics to Participate in the Lytham Partners..
09/9/202306:10EDGAR2Form 8-K - Current report
05/9/202322:00PRNUSCadrenal Therapeutics Highlights Additional Need for a New..
01/9/202306:05EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
01/9/202306:05EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
30/8/202322:00PRNUSCadrenal Therapeutics Expands Evaluation of Tecarfarin for..
29/8/202306:58EDGAR2Form ARS - Annual Report to Security Holders
29/8/202306:55EDGAR2Form DEF 14A - Other definitive proxy statements
29/8/202306:15PRNUSCadrenal Therapeutics to Participate in the H.C. Wainwright..
18/8/202320:06EDGAR2Form 8-K - Current report
17/8/202306:10EDGAR2Form 8-K - Current report
17/8/202306:05EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
10/8/202323:16EDGAR2Form 8-K - Current report
10/8/202323:00PRNUSCadrenal Therapeutics Provides Second Quarter 2023 Corporate..
10/8/202320:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/8/202323:00PRNUSCadrenal Therapeutics Expands Focus for Tecarfarin to..
01/8/202320:06EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
24/7/202323:20EDGAR2Form 8-K - Current report
24/7/202323:15EDGAR2Form S-1 - General form for registration of securities under..
24/7/202323:00PRNUSCadrenal Therapeutics Announces Appointment of Robert..
15/7/202306:52EDGAR2Form 8-K - Current report
15/7/202305:02PRNUSCadrenal Therapeutics Announces Closing of $7.5 Million..
13/7/202305:17PRNUSCadrenal Therapeutics Announces $7.5 Million Private..
01/6/202323:00PRNUSCadrenal Therapeutics to Participate in the 2023 BIO..

Your Recent History

Delayed Upgrade Clock